Ticker >

Mangalam Drugs&Org. share price

Mangalam Drugs And Organics Ltd.

NSE: MANGALAM BSE: 532637 SECTOR: Pharmaceuticals & Drugs  25k   57   6

112.60
+1.40 (1.26%)
BSE: 01 Nov 07:01 PM

Price Summary

Today's High

₹ 112.65

Today's Low

₹ 110.55

52 Week High

₹ 144.65

52 Week Low

₹ 85.16

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

178.23 Cr.

Enterprise Value

272.32 Cr.

No. of Shares

1.58 Cr.

P/E

56.17

P/B

1.23

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  91.63

CASH

1.01 Cr.

DEBT

95.1 Cr.

Promoter Holding

50.3 %

EPS (TTM)

₹  2

Sales Growth

-0.98%

ROE

-6.15 %

ROCE

1.23%

Profit Growth

-812.51 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.98%
3 Year-1.42%
5 Year10.12%

Profit Growth

1 Year-812.51%
3 Year-168.65%
5 Year-2.39%

ROE%

1 Year-6.15%
3 Year2.89%
5 Year8.15%

ROCE %

1 Year1.23%
3 Year8.74%
5 Year12.98%

Debt/Equity

0.6681

Price to Cash Flow

14.65

Interest Cover Ratio

0.2055

CFO/PAT (5 Yr. Avg.)

2.78694025196458

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 50.30 10.26
Jun 2024 50.32 14.88
Mar 2024 50.32 17.58
Dec 2023 50.32 18.08
Sep 2023 50.32 17.52
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 32.9385 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.78694025196458.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 28.2963281991816.

 Limitations

  • The company has shown a poor profit growth of -168.648299346752% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.41522344870163% for the Past 3 years.
  • Company has a poor ROE of 2.8880074694106% over the past 3 years.
  • Company has low Interest coverage ratio of 0.2055.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 87.47 81.56 97.34 102.24 76.54
Total Expenditure 90.94 79.36 90.36 90.54 68.35
Operating Profit -3.47 2.19 6.98 11.7 8.19
Other Income 0.02 0.03 0 0.05 0.02
Interest 3.41 3.25 3.31 3.95 3.75
Depreciation 3.42 3.73 3.62 3.86 3.87
Exceptional Items 0 0 0 0 0
Profit Before Tax -10.29 -4.75 0.04 3.94 0.59
Tax -0.75 -1.19 -0.46 0.39 -2.1
Profit After Tax -9.54 -3.56 0.5 3.55 2.69
Adjusted EPS (Rs) -6.02 -2.25 0.32 2.24 1.7

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 282.35 384.7 451.07 372.25 368.59
Total Expenditure 258.66 326.68 402.01 346.53 351.2
Operating Profit 23.69 58.02 49.05 25.72 17.39
Other Income 1.18 0 0.09 0.44 0.1
Interest 10.4 9.33 11.16 12.96 13.92
Depreciation 8.22 9.18 10.25 10.99 14.63
Exceptional Items 0 0 0 0 0
Profit Before Tax 6.25 39.52 27.73 2.21 -11.06
Tax -2 11.55 8.08 0.94 -2.01
Net Profit 8.25 27.97 19.66 1.27 -9.05
Adjusted EPS (Rs.) 5.21 17.67 12.42 0.8 -5.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 15.83 15.83 15.83 15.83 15.83
Total Reserves 88.11 114.96 134.73 136.13 126.52
Borrowings 4.17 6.88 25.1 18.77 13.35
Other N/C liabilities 13.09 17.37 22.65 23.55 20.49
Current liabilities 109.47 109.08 130.11 163.71 180.95
Total Liabilities 230.67 264.11 328.43 357.98 357.14
Assets
Net Block 101.07 117.82 134.96 142.36 147.31
Capital WIP 1.24 4.87 0.18 0 0
Intangible WIP 0 1.48 5.53 9.49 7.74
Investments 0.22 0.22 0 0 0.03
Loans & Advances 8.96 5.79 2.72 2.86 2.29
Other N/C Assets 0 0 0 0 0
Current Assets 119.17 133.92 185.03 203.26 199.78
Total Assets 230.67 264.11 328.43 357.98 357.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 6.25 39.52 27.73 2.21 -11.06
Adjustment 18.71 17.24 22.37 24.12 27.81
Changes in Assets & Liabilities 5.64 -19.94 -15.59 11.72 -4.39
Tax Paid -0.05 -9.27 -8.81 0.03 -0.19
Operating Cash Flow 30.55 27.55 25.71 38.08 12.17
Investing Cash Flow -6.87 -31.29 -27.33 -22.17 -17.91
Financing Cash Flow -23.48 2.7 2.98 -16.82 5.7
Net Cash Flow 0.2 -1.04 1.36 -0.91 -0.04

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 50.32 50.32 50.32 50.32 50.30
aditya r. dhoot 0.56 0.56 - 0.56 0.56
ajay r dhoot 0.88 0.88 - 0.88 0.88
brijmohan murlidhar dhoot... 0.49 0.49 3.57 0.49 0.49
dhoot brijmohan murlidhar... 3.08 3.08 - 3.08 3.08
dhoot goverdhan murlidhar... 3.23 3.23 - - 3.23
dhoot jyoti brijmohan 0.66 0.66 0.66 0.66 0.66
dhoot rekha goverdhan 0.94 0.94 - 0.94 0.93
govardhan murlidhar dhoot... 0.98 0.98 4.21 0.98 0.98
radhika a dhoot 1.85 1.85 - 1.85 1.85
raj exports private limit... - - 1.21 1.21 1.21
rajkamal sukhani 0.18 0.18 0.18 0.18 0.18
rajkumari r. dhoot 1.74 1.74 - 1.74 1.74
shree kishoriju trading &... - - - - 6.94
shree rasbihari trading &... - - - - 6.39
shri jb pharma private li... 16.74 16.74 16.74 16.74 16.74
shweta goverdhan dhoot 2.59 2.59 - 2.59 2.59
smita a. dhoot 1.85 1.85 - 1.85 1.85
dhoot govardhan murlidhar... - - - 3.23 -
shree kishoriju trading a... - - 6.94 6.94 -
shree rasbihari trading a... - - 6.39 6.39 -
aditya ramniwas dhoot - - 0.56 - -
ajay ramniwas dhoot - - 0.88 - -
dhoot rekha govardhan - - 0.94 - -
radhika ajay dhoot - - 1.85 - -
rajkumari ramniwas dhoot - - 1.74 - -
shweta govardhan dhoot - - 2.59 - -
smita aditya dhoot - - 1.85 - -
raj exports pvt ltd 1.21 1.21 - - -
shree kishoriju trading &... 6.94 6.94 - - -
shree rasbihari trading &... 6.39 6.39 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 49.68 49.68 49.68 49.68 49.70
ambika food industries pr... 1.04 1.04 1.04 1.04 1.04
ashutosh taparia 1.91 - 1.91 1.91 1.91
jyotiprasad taparia 1.33 - 1.33 1.33 1.33
llp 0.16 0.16 0.14 0.14 0.17
ashutosh taparia - 1.91 - - -
jyotiprasad taparia - 1.33 - - -
ajay upadhyaya 1.90 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Mangalam Drugs & Organics informs about trading window closure1 Oct 2024, 2:53PM Mangalam Drugs secures grant from MMV for research, development of Pyronaridine26 Aug 2024, 12:16PM Mangalam Drugs expanding anti-malaria API portfolio with Pyronaridine20 Aug 2024, 12:08PM Mangalam Drugs&Org. - Quaterly Results13 Aug 2024, 7:53PM Mangalam Drugs&Org. - Quaterly Results21 May 2024, 7:35PM Mangalam Drugs&Org. - Quaterly Results21 May 2024, 7:35PM Mangalam Drugs & Organics informs about certificate25 Apr 2024, 4:47PM Mangalam Drugs & Organics informs about outcome of board meeting16 Mar 2024, 3:38PM Mangalam Drugs & Organics informs about disclosures2 Mar 2024, 12:32PM Mangalam Drugs&Org. - Quaterly Results13 Feb 2024, 7:39PM Mangalam Drugs&Org. - Quaterly Results13 Feb 2024, 7:39PM Mangalam Drugs & Organics informs about board meeting6 Feb 2024, 5:25PM Mangalam Drugs & Organics informs about disclosure 28 Nov 2023, 10:42AM Mangalam Drugs&Org. - Quaterly Results10 Aug 2023, 5:50PM Mangalam Drugs&Org. - Quaterly Results10 Aug 2023, 5:50PM Mangalam Drugs & Organics informs about compliances-certificate 25 Jul 2023, 4:00PM Mangalam Drugs&Org. - Quaterly Results30 May 2023, 6:56PM Mangalam Drugs & Organics informs about proceeds of postal ballot2 May 2023, 4:55PM Mangalam Drugs & Organics informs about disclosure 24 Mar 2023, 10:54AM Mangalam Drugs & Organics informs about disclosure21 Mar 2023, 5:18PM Mangalam Drugs&Org. - Quaterly Results13 Feb 2023, 7:06PM Mangalam Drugs & Organics informs about disclosures 3 Dec 2022, 12:11PM Mangalam Drugs & Organics informs about disclosure26 Aug 2022, 10:13AM Mangalam Drugs & Organics informs about disclosure 23 Aug 2022, 10:08AM Mangalam Drugs & Organics informs about disclosures 19 Aug 2022, 3:51PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs&Org. - Quaterly Results5 Aug 2022, 5:05PM Mangalam Drugs & Organics informs about disclosures 2 Jul 2022, 4:48PM Mangalam Drugs & Organics informs about disclosure4 Jun 2022, 10:34AM Mangalam Drugs & Organics informs about compliance certificate8 Apr 2022, 3:47PM Mangalam Drugs & Organics informs about closure of trading window28 Mar 2022, 5:13PM Mangalam Drugs & Organics informs about disclosure5 Mar 2022, 3:43PM Mangalam Drugs & Organics informs about disclosure2 Mar 2022, 5:12PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs&Org. - Quaterly Results4 Feb 2022, 5:18PM Mangalam Drugs & Organics informs about board meeting4 Aug 2021, 3:42PM Mangalam Drugs & Organics informs about disclosure3 Aug 2021, 10:16AM Mangalam Drugs and Organics commissioning new intermediate manufacturing facility at Gujarat18 Jun 2021, 3:44PM Mangalam Drugs & Organics informs about disclosure of related party transactions11 Jun 2021, 4:53PM Mangalam Drugs and Organics gets CEP for Hydroxychloroquine Sulphate20 May 2020, 10:48AM

Mangalam Drugs&Org. Stock Price Analysis and Quick Research Report. Is Mangalam Drugs&Org. an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mangalam Drugs&Org. and its performance over the period of time. Mangalam Drugs&Org. stock price today is Rs 112.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mangalam Drugs&Org. cash from the operating activity was Rs 12.1681 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mangalam Drugs&Org. has a Debt to Equity ratio of 0.6681 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mangalam Drugs&Org. , the EPS growth was -812.4751 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mangalam Drugs&Org. has OPM of 4.71892297963048 % which is a bad sign for profitability.
     
  • ROE: Mangalam Drugs&Org. have a poor ROE of -6.1494 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mangalam Drugs&Org. is Rs 112. One can use valuation calculators of ticker to know if Mangalam Drugs&Org. share price is undervalued or overvalued.
Last Updated on:
Brief about Mangalam Drugs&Org.
X